These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 37392367)

  • 1. Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015).
    Kim M; Lee JJ; Min CK; Lee JY; Jo JC; Yoon SS; Lim SN; Do YR; Kim K; Lee JH; Yoo KH; Bae SH; Yi JH; Jung J; Eom HS; Jung SH
    Ann Hematol; 2023 Aug; 102(8):2233-2240. PubMed ID: 37392367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis.
    Song GY; Jung SH; Lee JJ; Kim JS; Min CK; Kim K; Choi Y; Eom HS; Joo YD; Kim SH; Kwak JY; Kang HJ; Lee JH; Lee HS; Mun YC; Moon JH; Sohn SK; Park SK; Park Y; Shin HJ; Yoon SS
    Leuk Lymphoma; 2020 Nov; 61(11):2714-2721. PubMed ID: 32580672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Busulfan plus melphalan
    Park S; Shin DY; Hong J; Kim I; Koh Y; Byun JM; Yoon SS
    Ther Adv Hematol; 2021; 12():20406207211012985. PubMed ID: 33995990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma.
    Byun JM; Lee J; Shin SJ; Kang M; Yoon SS; Koh Y
    Blood Res; 2018 Jun; 53(2):105-109. PubMed ID: 29963515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m
    Gao F; Lin MS; You JS; Zhang MY; Cheng L; Lin K; Zhao P; Chen QY
    Cancer Cell Int; 2021 Nov; 21(1):601. PubMed ID: 34758834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study.
    Park SS; Kim K; Kim SJ; Lee JH; Yoon SS; Mun YC; Lee JJ; Eom HS; Kim JS; Min CK;
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1312-1319. PubMed ID: 30910603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission-Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Gorin NC; Labopin M; Czerw T; Pabst T; Blaise D; Dumas PY; Nemet D; Arcese W; Trisolini SM; Wu D; Huynh A; Zuckerman T; Meijer E; Cagirgan S; Cornelissen J; Houhou M; Polge E; Mohty M; Nagler A
    Cancer; 2017 Mar; 123(5):824-831. PubMed ID: 27906458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma.
    Lahuerta JJ; Grande C; Blade J; Martínez-López J; de la Serna J; Alegre A; Garcia LJ; Caballero D; de la Rubia J; Marín J; Perez-Lopez C; Sureda A; Escudero A; Cabrera R; Conde E; García-Ruiz JC; Pérez-Equiza K; Hernandez F; Palomera L; León A; Giraldo P; Solano C; Bargay J; San MJ;
    Leuk Lymphoma; 2002 Jan; 43(1):67-74. PubMed ID: 11908738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma.
    Lahuerta JJ; Martinez-Lopez J; Grande C; Bladé J; de la Serna J; Alegre A; García-Laraña J; Caballero D; Sureda A; de la Rubia J; Alvarez AM; Marín J; Escudero A; Conde E; Perez-Equiza K; García Ruiz JC; Moraleda JM; León A; Bargay J; Cabrera R; Hernandez-García MT; Diaz-Mediavilla J; Miguel JS
    Br J Haematol; 2000 Apr; 109(1):138-47. PubMed ID: 10848793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploratory analysis of intensified conditioning as first line treatment for patients with high risk multiple myeloma.
    Bommier C; Talbot A; Harel S; Cuccuini W; Gérard L; Arnulf B
    Hematol Oncol; 2020 Oct; 38(4):517-522. PubMed ID: 32569436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
    Sanz J; Labopin M; Pabst T; Versluis J; Van Gorkom G; Meijer E; Gedde-Dahl T; Montoro J; Arcese W; Pérez-Simón JA; Schaap N; Maertens J; Vrhovac R; Lanza F; Gorin NC; Mohty M; Ciceri F
    Bone Marrow Transplant; 2023 Nov; 58(11):1197-1202. PubMed ID: 37553468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT.
    Gorin NC; Labopin M; Blaise D; Dumas PY; Pabst T; Trisolini SM; Arcese W; Houhou M; Mohty M; Nagler A
    Am J Hematol; 2018 Jul; 93(7):859-866. PubMed ID: 29644709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts.
    Nieto Y; Yang Z; Valdez BC; Kundu S; Bashir Q; Ramdial J; Srour S; Qazilbash M
    Am J Hematol; 2024 Feb; 99(2):245-253. PubMed ID: 38100199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
    Nieto Y; Valdez BC; Pingali SR; Bassett R; Delgado R; Nguyen J; Shah N; Popat U; Jones RB; Andersson BS; Gulbis A; Ahmed S; Bashir Q; Parmar S; Patel K; Myers A; Rondon G; Orlowski RZ; Champlin R; Qazilbash M
    Lancet Haematol; 2017 Jun; 4(6):e283-e292. PubMed ID: 28522110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Busulfan, melphalan and carfilzomib high-dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma.
    Hagen P; Norton J; Tsai S; Campo L; Lee M; Gomez K; Stiff P
    Br J Haematol; 2024 Apr; 204(4):1422-1428. PubMed ID: 38176404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.
    Bashir Q; Thall PF; Milton DR; Fox PS; Kawedia JD; Kebriaei P; Shah N; Patel K; Andersson BS; Nieto YL; Valdez BC; Parmar S; Rondon G; Delgado R; Hosing C; Popat UR; Oran B; Ciurea SO; Lin P; Weber DM; Thomas SK; Lee HC; Manasanch EE; Orlowski RZ; Williams LA; Champlin RE; Qazilbash MH
    Lancet Haematol; 2019 May; 6(5):e266-e275. PubMed ID: 30910541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities.
    Guman T; Sykora J
    Bratisl Lek Listy; 2024; 125(1):9-11. PubMed ID: 38041839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.